Risk factors for VZV disease after 1 year (univariate analysis)
. | . | Modified intent-to-treat cohort . | . | . | ||
|---|---|---|---|---|---|---|
| Variable . | Comparison . | HR . | 95% CI . | P . | ||
| Study medication | Acyclovir vs placebo | 1.9 | 0.67, 5.2 | .22 | ||
| Ongoing use of immunosuppressive drugs* | Yes vs no | 3.1 | 1.2, 8.3 | .02 | ||
| Sex | Male vs female | 1.2 | 0.48, 3.1 | .68 | ||
| Age at transplantation | 10 years and older | 1.2 | 0.76, 1.8 | .47 | ||
| HLA match | MM/UR vs matched | 3.5 | 1.1, 11 | .05 | ||
| Ongoing use of immunosuppressive drugs* or MM/UR donor status | Immune suppressive or MM/UR vs others | 3.5 | 1.3, 9.9 | .01 | ||
. | . | Modified intent-to-treat cohort . | . | . | ||
|---|---|---|---|---|---|---|
| Variable . | Comparison . | HR . | 95% CI . | P . | ||
| Study medication | Acyclovir vs placebo | 1.9 | 0.67, 5.2 | .22 | ||
| Ongoing use of immunosuppressive drugs* | Yes vs no | 3.1 | 1.2, 8.3 | .02 | ||
| Sex | Male vs female | 1.2 | 0.48, 3.1 | .68 | ||
| Age at transplantation | 10 years and older | 1.2 | 0.76, 1.8 | .47 | ||
| HLA match | MM/UR vs matched | 3.5 | 1.1, 11 | .05 | ||
| Ongoing use of immunosuppressive drugs* or MM/UR donor status | Immune suppressive or MM/UR vs others | 3.5 | 1.3, 9.9 | .01 | ||
MM indicates HLA-mismatched donor; UR, unrelated donor.
Ongoing immunosuppression was defined as continued use of systemic immunosuppressive drugs